Origin and therapy for hypertriglyceridaemia in type 2 diabetes

查看全文 作　　者：Jing [1]Pang;Dick C [1]Chan;Gerald F [2,3]Watts

机构地区：[1]School of Medicine and Pharmacology, University of Western Australia;[2]School of Medichne and Pharmacology, University of Western Australia;[3]Lipid Disorders Clinic, Royal Perth Hospital

出　　处：《World Journal of Diabetes》索引2014年第5卷第2期,共11页

摘　　要：Hypertriglyceridaemia(HTG) is a risk factor for cardiovascular disease(CVD) in type 2 diabetes and is caused by the interaction of genes and non-genetic factors, specifically poor glycaemic control and obesity. In spite of statin treatment, residual risk of CVD remains high in type 2 diabetes, and this may relate to HTG and atherogenic dyslipidemia. Treatment of HTG emphasises correcting secondary factors and adverse lifestyles, in particular, diet and exercise. Pharmacotherapy is also required in most type 2 diabetic patients. Statins are the first-line therapy to achieve recommended therapeutic targets of plasma low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Fibrates, ezetimibe and n-3 fatty acids are adjunctive treatment options for residual and persistent HTG. Evidence for the use of niacin has been challenged by non-significant CVD outcomes in two recent large clinical trials. Further investigation is required to clarify the use of incretin-based therapies for HTG in type 2 diabetes. Extreme HTG, with risk of pancreatitis, may require insulin infusion therapy or apheresis.New therapies targeting HTG in diabetes need to be tested in clinical endpoint trials. The purpose of this review is to examine the current evidence and provide practical guidance on the management of HTG in type 2 diabetes. 关键词：DIABETES TRIGLYCERIDE Therapy

相关文献

参考文献（62）
引证文献（2）
耦合文献（6）

参考文献(62)

引证文献(2)

耦合文献(6)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Origin and therapy for hypertriglyceridaemia in type 2 diabetes

参考文献(62)

引证文献(2)

耦合文献(6)

用户提示